For the Inventor, By the Inventor

Enter assignee name

Berkeley Heights, NJ, United States of America

Genta Incorporated

USPTO Granted Patents = 31

Forward Citations = 654

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

David Aaron Schwartz (10 out of 47 patents)

Mark A Reynolds (9 out of 29 patents)

Lyle J Arnold, Jr (9 out of 26 patents)

4. Timothy Andrew Riley (7 out of 8 patents)

5. Robert E Klem (6 out of 8 patents)

6. Brian Patrick Dwyer (5 out of 15 patents)

7. Bob Dale Brown (5 out of 92 patents)

8. William J Daily (5 out of 7 patents)

9. Morteza M Vaghefi (4 out of 5 patents)

10. Thomas N Julian (3 out of 9 patents)

11. Kumar Srinivasan (3 out of 5 patents)

12. Richard I Hogrefe (2 out of 18 patents)

13. Raymond P Warrell, Jr (2 out of 31 patents)

14. Cristina Giachetti (2 out of 6 patents)

15. Raymond P Warrell (1 out of 1 patent)

31 patents: Sort by Forward Citations

1. 7855183 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers (2010-12-21),

2. 7842724 - Pharmaceutical gallium compositions and methods (2010-11-30),

3. 7795232 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers (2010-09-14),

4. 7456215 - Pharmaceutical gallium compositions and methods (2008-11-25),

5. 7354952 - Pharmaceutical gallium compositions and methods (2008-04-08),

6. 7256284 - Inhibitory oligonucleotides targeted to Bcl-2 (2007-08-14),

7. 7119217 - Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them (2006-10-10),

8. 7060690 - Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof (2006-06-13),

9. 6638529 - Amide-based cationic lipids (2003-10-28),

10. 6262036 - Method for inhibiting RNA translation using chimeric oligonucleoside compounds (2001-07-17),

11. 6060456 - Chimeric oligonucleoside compounds (2000-05-09),

12. 6028188 - Synthetic oligomers having chirally pure phosphonate internucleosidyl (2000-02-22),

13. 6020526 - Amide-based cationic lipids (2000-02-01),

14. 6005094 - Oligonucleotide analogues having improved stability at acid pH (1999-12-21),

15. 5986083 - Synthetic oligomers having phosphonate internucleosidyl linkages of (1999-11-16),

Genta Incorporated is a leading pharmaceutical company specialized in the research, development, and commercialization of innovative treatment options for cancer. With a dedicated team of experts and a strong commitment to improving patient outcomes, Genta Inc. focuses on developing targeted therapies that address unmet medical needs. We continuously strive to push the boundaries of scientific discovery and deliver breakthrough solutions that can make a real difference in the lives of cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

31 Patents

#4 in Berkeley Heights, NJ

#429 in New Jersey

#10,543 in US

#20,605 in the World

Berkeley Heights, NJ, United States of America

Genta Incorporated

Forward Citations = 654

37 inventors:

David Aaron Schwartz (10 out of 47 patents)

Mark A Reynolds (9 out of 29 patents)

Lyle J Arnold, Jr (9 out of 26 patents)

4. Timothy Andrew Riley (7 out of 8 patents)

5. Robert E Klem (6 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…